ArticleOncotarget2017
MicroRNA-744 promotes prostate cancer progression through aberrantly activating Wnt/β-catenin signaling.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 50 citations in OpenAlex.
- A novel ferroptosis-related microRNAs signature for predicting prognosis in endometrial cancer: An observational study.Medicine · 2025Observational
- Role of multi‑omics in advancing the understanding and treatment of prostate cancer (Review).Molecular medicine reports · 2025Review
- Article
- Unlocking the role of non-coding RNAs in prostate cancer progression: exploring the interplay with the Wnt signaling pathway.Frontiers in pharmacology · 2023Review
- miR-182 promotes cervical cancer progression via activating the Wnt/β-catenin axis.American journal of cancer research · 2023Article
- MiRNA expression profiling in adenocarcinoma and squamous cell lung carcinoma reveals both common and specific deregulated microRNAs.Medicine · 2022Article
- Dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspective.Oncology research · 2022Review
- Wnt/β-catenin signal transduction pathway in prostate cancer and associated drug resistance.Discover oncology · 2021Review
- MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro.Scientific reports · 2021Article
- MicroRNA-4429 suppresses proliferation of prostate cancer cells by targeting distal-less homeobox 1 and inactivating the Wnt/β-catenin pathway.BMC urology · 2021Article
- miR-541-3p enhances the radiosensitivity of prostate cancer cells by inhibiting HSP27 expression and downregulating β-catenin.Cell death discovery · 2021Article
- Article
- MicroRNA-188-5p targeting Forkhead Box L1 promotes colorectal cancer progression via activating Wnt/β-catenin signaling.Oncology research · 2021Article
- miR-744-5p inhibits cellular proliferation and invasion via targeting ARF1 in epithelial ovarian cancer.The Kaohsiung journal of medical sciences · 2020Article
- Prostate cancer-derived holoclones: a novel and effective model for evaluating cancer stemness.Scientific reports · 2020Article
- Oncogenic and tumor-suppressive microRNAs in prostate cancer.Current opinion in endocrine and metabolic research · 2020Article
- MicroRNA-744 promotes carcinogenesis in osteosarcoma through targeting LATS2.Oncology letters · 2019Article
- MicroRNA-200a suppresses prostate cancer progression through BRD4/AR signaling pathway.Cancer medicine · 2019Article
- Oncogenic miR-744 promotes prostate cancer growth through direct targeting of LKB1.Oncology letters · 2019Article
- Human CAP cells represent a novel source for functional, miRNA-loaded exosome production.PloS one · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulated evidence indicate that miR-744 functions as either tumor suppressor or oncogene in the progression of a variety of tumors, with a tumor type-specific way. However, little is known about how miR-744 impacts on the tumorigenesis of human prostate cancer. In this study, employing the analyses of microarray, qRT-PCR and re-analysis of MSKCC data, we found that CRPC tissues expressed much more miR-744 than ADPC tissues did, and the expression level of miR-744 was inversely associated with survival of CRPC patients. In vitro studies revealed that miR-744 promotes PCa cells proliferation, enhances migration, invasion; in vivo results demonstrated that silencing of miR-744 mediated by shRNA dramatically reduces PCa xenograft tumor growth. Importantly, through human gene expression array, pathway enrichment analysis and Western blot, we identified that miR-744 dramatically activated Wnt/β-catenin pathway by targeting multiple negative regulators of Wnt/β-catenin signaling, including SFRP1, GSK3β, TLE3 and NKD1. At molecular level, we further defined that NKD1 is a major functional target of miR-744. Our findings indicate that miR-744 acts as one of oncogenic factor in the progression of CRPC by recruiting a mechanism of aberrant activation of Wnt/β-catenin signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.